
-
Fulcrum Therapeutics NASDAQ:FULC Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.
Location: | Website: www.fulcrumtx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-41.98M
Cash
273.8M
Avg Qtr Burn
-3.112M
Short % of Float
12.29%
Insider Ownership
1.62%
Institutional Own.
89.70%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pociredir (FTX-6058) Details Sickle cell disease | Phase 1b Data readout | |
Losmapimod Details COVID-19 | Failed Discontinued | |
Losmapimod Details Muscle degeneration, Muscle weakness, Facioscapulohumeral muscular dystrophy | Failed Discontinued |